Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yvette Henin is active.

Publication


Featured researches published by Yvette Henin.


Journal of Biological Chemistry | 2000

Grb3-3 Is Up-regulated in HIV-1-infected T-cells and Can Potentiate Cell Activation through NFATc

Xuguang Li; Marie-Christine Multon; Yvette Henin; Fabien Schweighoffer; Corinne Venot; Juliana Josef; Changhong Zhou; Joyce Lavecchio; Patricia Stuckert; Monika Raab; Abner M. Mhashilkar; Bruno Tocque; Wayne A. Marasco

The MAPK pathway is required for T-cell activation; however, its role in modulating T-cell function following human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. In this report, we investigated whether Grb3-3, an isoform of the Grb2 (growth factorreceptor-bound protein-2) adaptor molecule that is associated with the MAPK pathway, could be involved. We found that Grb3-3, but not its isoform Grb2, is markedly up-regulated in CD4+ peripheral blood mononuclear cells derived from either in vitro HIV-1-infected cultures or HIV-1-infected human subjects. Analysis of HIV-1 gene products indicated that Tat and Nef, both of which have been implicated in modulating T-cell function, can independently induce expression of Grb3-3. By using NFAT/AP-1, AP-1, or NFAT reporter assays, we found that Grb3-3 can potentiate NFAT (but not AP-1) promoter activity in Jurkat T-cells upon engagement of the T-cell receptor and CD28 co-receptor. In addition, potentiation of NFAT by Grb3-3 is substantially suppressed by MEKK1, a kinase that may play an important role in retaining NFAT in the cytoplasm, and by cyclosporin A. Finally, we also found that Grb3-3 potentiates HIV-1 long terminal (LTR) repeat promoter activity following T-cell receptor stimulation, an effect that can be largely suppressed by cyclosporin A. Taken together, this study indicates that Grb3-3 is a cellular factor that can be up-regulated by HIV-1. In addition, Grb3-3 can also function as a positive factor for T-cell activation and, in doing so, may aid in establishing an intracellular environment that can optimally support HIV-1 replication.


Proceedings of the National Academy of Sciences of the United States of America | 1994

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

Jean-Francois Mayaux; Anne Bousseau; Rudi Pauwels; Thierry Huet; Yvette Henin; Norbert Dereu; Michel Evers; Francoise Soler; Christèle Poujade; E. De Clercq


Journal of Medicinal Chemistry | 1996

Betulinic Acid Derivatives: A New Class of Human Immunodeficiency Virus Type 1 Specific Inhibitors with a New Mode of Action

Michel Evers; Christèle Poujade; Francoise Soler; Yves Ribeill; Claude James; Yves Lelièvre; Jean-Christophe Gueguen; Daniel Reisdorf; Isabelle Morize; Rudi Pauwels; Erik De Clercq; Yvette Henin; Anne Bousseau; Jean-Francois Mayaux; and Jean-Bernard Le Pecq; Norbert Dereu


Journal of Medicinal Chemistry | 1996

Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.

Francoise Soler; Christèle Poujade; Michel Evers; Jean-Christophe Carry; Yvette Henin; Anne Bousseau; Thierry Huet; Rudi Pauwels; Erik De Clercq; Jean-Francois Mayaux; and Jean-Bernard Le Pecq; Norbert Dereu


Archive | 2004

Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean


Bioorganic & Medicinal Chemistry Letters | 2003

Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs

Michel Evers; Jean-Claude Barriere; Georges Bashiardes; Anne Bousseau; Jean-Christophe Carry; Norbert Dereu; Bruno Filoche; Yvette Henin; Serge Sablé; Marc Vuilhorgne; Serge Mignani


Journal of Medicinal Chemistry | 1997

Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs

David R. Adams; Caroline Perez; Michel Maillard; Jean-Claude Florent; Michel Evers; Yvette Henin; Simon Litvak; Laura Litvak; Claude Monneret; David S. Grierson


Archive | 2002

Compositions for the treatment of Parkinson's disease containing a CB1 receptor antagonist and a product that activates the dopaminergic neurotransmission in the brain.

Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean


Archive | 2002

Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain

Jesus Benavides; Daniel Boccio; Yvette Henin; Odile Piot-Grosjean


Biochemical and Biophysical Research Communications | 2000

Upregulation of the apoptosis-associated protein Grb3-3 in HIV-1-infected human CD4(+) lymphocytes.

Xuguang Li; Marie-Christine Multon; Yvette Henin; Fabien Schweighoffer; Corinne Venot; Joyce Lavecchio; Juliana Josef; Patricia Stuckert; Abner M. Mhashilkar; Bruno Tocque; Wayne A. Marasco

Collaboration


Dive into the Yvette Henin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge